If the result is reproduced in planned phase 2b/3 studies, Cerevance could be in the running to bring a Parkinson's therapy to market that works via an entirely new mechanism of action.

HF medications investigated were angiotensin receptor blockers, ACE inhibitors, beta-blockers, loop diuretics and mineralocorticoid receptor antagonists. Cox regression, stratified by sex and age, ...

This document does not contain recommendations for other forms of electrocardiographic monitoring, including the static 12-lead ECG, exercise testing, or ambulatory electrocardiographic (Holter) ...